Massachusetts Moves Forward In Decriminalizing Psychedelics

Massachusetts lawmakers are moving forward to decriminalize psychedelic drugs. T

Read more
Psychedelic Drug Stocks Then-And-Now: Six Months Ago Versus Today

Psychedelic stocks are well off of their 2020 highs. But they are even further from their 2020 lows. Opportunity knocks.

Read more
New Jersey Gov. Signs Bill to Legalize Cannabis

After over three months since voters approved the state’s cannabis legalization ballot question, New Jersey Gov. Phil Murphy (D) today signed into law a series of bills that ultimately legalize the adult use of cannabis.

Read more
Why Is Everyone So Obsessed With Mushrooms Right Now?

It used to be that the only time I really saw mushrooms was when a few white button mushrooms appeared on a garden salad or atop my cheese pizza.

Read more
Proposed California Psychedelics Bill Would Be Sector Turning Point

California’s new proposed psychedelics “decriminalization” would, in fact, LEGALIZE possession of many psychedelic substances.

Read more
MINDCURE’s Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization

MINDCURE adds bioinformatics to its drug development platform.

Read more
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics

Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE’s psychedelic drug research on traumatic brain injury

Read more
MINDCURE’s Psychedelics R&D Targets Blockbuster TBI Treatment Market

MINDCURE’s R&D on traumatic brain injury (TBI) targets the LARGEST individual market for psychedelic drugs.

Read more
Can LSD cure our pandemic anxiety? MindMed is spending big to find out

While many people will look back on the pandemic as a dark time, it has also spurred some positive developments—most notably in the field of drug development, where miraculous breakthroughs like mRNA vaccines are transforming immunology.

Read more
Mindset Pharma Added to North American Psychedelics Index

Toronto, Ontario– Mindset Pharma Inc., a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that effective today, it has been added to the North American Psychedelics Index which is provided by German-based index provider, Solactive.

Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )